Clinical Trials on Cholelithiasis; Bile Duct in Australia

Total 55 results

Kepler University Hospital

Completed

Intraoperative ERCP Versus Therapeutic Splitting in Cholecysto-, Choledocholithiasis

Cholelithiasis, Common Bile Duct

Austria
South West Sydney Local Health District
Sydney South West Area Health Service; Northern Sydney and Central Coast Area... and other collaborators

Terminated

Management of Common Bile Duct (CBD) Stones at Laparoscopic Cholecystectomy

Cholelithiasis | Choledocholithiasis

Australia
University of Salzburg
Biolitec Pharma Ltd.

Unknown

Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

Non-curative Resectable Bile Duct Carcinoma

Austria, Germany
HighTide Biopharma Pty Ltd

Completed

A Study of HTD1801 in Healthy Subjects

Primary Sclerosing Cholangitis

Australia
Dr. Falk Pharma GmbH

Completed

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis (NUC-3)

Primary Sclerosing Cholangitis

Austria, Germany, Norway
Dr. Falk Pharma GmbH

Recruiting

norUrsodeoxycholic Acid vs Placebo in PSC

Primary Sclerosing Cholangitis

Austria, Germany
University Hospital Plymouth NHS Trust
University of Plymouth

Completed

Recurrence After Whipple's (RAW) Study

Pancreatic Cancer | Surgery | Bile Duct Cancer | Pancreatic Ductal Adenocarcinoma | Survivorship | Cholangiocarcinoma, Extrahepatic | Cancer Recurrence | Recurrent Cancer | Pancreatic Ductal Carcinoma | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampullary Cancer | Cholangiocarcinoma Resectable | Cancer... and other conditions

Spain, United Kingdom, Australia, Austria, Italy, Mexico, Sudan, Pakistan
Boston Scientific Corporation

Completed

WallFlex Biliary Fully Covered (FC) Benign Stricture Study

Biliary Stricture

Netherlands, Australia, Canada, Austria, France, Belgium, Chile, Germany, India, Italy, Spain
Albireo

Completed

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2 (PEDFIC 1)

PFIC1 | PFIC2

United States, Spain, Netherlands, United Kingdom, Turkey, Canada, Belgium, Italy, Germany, Saudi Arabia, France, Israel, Australia, Sweden, Poland
Pliant Therapeutics, Inc.

Completed

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis

United States, Belgium, Australia, Canada, Netherlands, Germany, Austria, United Kingdom, France
Mirum Pharmaceuticals, Inc.

Active, not recruiting

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (MERGE)

Cholestatic Liver Disease

United States, France, United Kingdom, Canada, Belgium, Poland, Australia, Spain
Medical University of Graz

Active, not recruiting

Secondary Sclerosing Cholangitis in Critically Ill Patients (SSC-CIP)

Secondary Sclerosing Cholangitis

Austria
Boston Scientific Corporation

Completed

SpyGlass AMEA Registry

Biliary Stricture | Periampullary Tumor | Biliary Obstruction Due to Common Bile Duct Stone | Hemobilia

Hong Kong, Korea, Republic of, Thailand, Australia, Saudi Arabia, Japan, India, Pakistan, Singapore, South Africa
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
Gilead Sciences

Terminated

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis (PRIMIS)

Primary Sclerosing Cholangitis

United States, Belgium, Israel, Spain, United Kingdom, Australia, Germany, New Zealand, Denmark, France, Japan, Switzerland, Austria, Canada, Finland, Italy
Boston Scientific Corporation

Completed

WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study

Biliary Stricture

Australia, France, Belgium, Hong Kong, Canada, Italy, Austria, Germany, India, Netherlands, Sweden
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Primary Sclerosing Cholangitis

United States, Canada, United Kingdom, Austria
Medical University of Vienna

Completed

Preventing Cholestasis Using SMOFLipid®

Cholestasis | Psychomotor Disorders, Developmental

Austria
Medical University of Graz

Recruiting

Secondary Sclerosis Cholangitis Prospective (SSCpro)

Secondary Sclerosis Cholangitis in Critically Ill Patients

Austria
OncoC4, Inc.
Avance Clinical; OncoC4 AU Pty Ltd

Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditions

Australia
Albireo

Active, not recruiting

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Progressive Familial Intrahepatic Cholestasis

United States, Spain, Netherlands, United Kingdom, Turkey, Canada, Italy, Germany, France, Israel, Australia, Belgium, Poland, Saudi Arabia, Sweden
Albireo

Enrolling by invitation

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia (BOLD-EXT)

Biliary Atresia

Spain, United States, Netherlands, Malaysia, Canada, Germany, Turkey, Italy, France, Australia, Poland, New Zealand
Escient Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

Pruritus | Cholestasis | Kidney Failure

Australia, New Zealand
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Medical University of Vienna

Unknown

Hemopatch for Prevention of Bile Leaks After Liver Resection

Bile Leak

Austria
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
Albireo

Recruiting

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Biliary Atresia

Netherlands, United States, Spain, Italy, Taiwan, Korea, Republic of, France, Germany, United Kingdom, Canada, Belgium, China, Australia, Poland, Turkey, Malaysia, New Zealand, Hungary, Israel
Elevation Oncology

Active, not recruiting

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bladder Cancer | Metastatic Solid Tumor | Gallbladder Cancer | Uterine Cancer | Locally Advanced Solid Tumor

United States, Korea, Republic of, Australia, Canada
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
Medical University of Graz

Completed

Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis

Hypercholesterolemia | Primary Biliary Cirrhosis

Austria
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
Intercept Pharmaceuticals

Terminated

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, Spain, Canada, United Kingdom, France, Germany, Austria, Netherlands
Mirum Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, Argentina, France, Singapore, United Kingdom, Belgium, Turkey, Austria, Brazil, Canada, Colombia, Germany, Italy, Lebanon, Mexico, Poland
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM)

Primary Biliary Cholangitis | Liver Stiffness

United States, Spain, France, Australia, Israel, Canada, Switzerland, Italy, New Zealand, Germany, Poland, Greece, United Kingdom, Belgium, Austria, Czechia, Hungary, Sweden
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Kepler University Hospital

Completed

Warmed, Humidified Carbon Dioxide Insufflation vs Standard Carbon Dioxide in Laparoscopic Cholecystectomy

Cholecystolithiasis

Austria
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
St John of God Hospital, Vienna

Completed

SILS Cholecystectomy: Cholangiography of the Biliary Tract

Cholecystolithiasis

Austria
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
GlaxoSmithKline

Completed

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Cholestasis

United States, Australia, France, Spain, Germany, Canada, Japan, United Kingdom, Italy, Poland
Medical University of Vienna

Completed

Nasolacrimal Duct Obstruction

Eye Diseases | Lacrimal Duct Obstruction

Austria
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)

Alagille Syndrome

France, Belgium, Poland, Australia, Spain, United Kingdom
Medical University of Vienna

Unknown

Omega Loop Gastric Bypass With And Without Anti-Reflux Sutures

Bile Reflux

Austria

Clinical Trials on Cholelithiasis; Bile Duct in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations